Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).
The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.
Vanderbilt engineers have developed a robotic system for performing sinus and neurosurgery through the nose. This provides a less invasive way to access surgical sites in the sinuses and near the middle of the patient's head, leading to faster recovery times. The robot is modular and sterilizable with detachable cartridge-based instruments. Each instrument is a concentric tube robot, which is a needle-sized tool that can bend and elongate. The system delivers four of these instruments through a single nostril.